Skip to main content
padlock icon - secure page this page is secure

Small-Molecule CSF1R Inhibitors as Anticancer Agents

Buy Article:

Price: $68.00 + tax (Refund Policy)

Persuasive evidence has been presented linking the infiltration of tumor-associated macrophages (TAMs) with the driving force of tumorigenesis and in the suppression of antitumor immunity. In this context CSF1R, the cellular receptor for colony stimulating factor-1 (CSF1) and interleukin 34 (IL-34), occupies a central role in manipulating the behavior of TAMs and the dysregulation of CSF1R signaling has been implicated in cancer progression and immunosuppression in many specific cancers. Consequently, CSF1R kinase has been a target of great interest in cancer treatment and significant research efforts have focused on the development of smallmolecule CSF1R inhibitors. In this review, we highlight current progress on the development of these small molecule CSF1R inhibitors as anticancer agents. Special attention is paid to the compounds available in advanced clinical trials.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: CSF1R; Tumor-associated macrophages; anticancer agents; clinical trials; inhibitors; pharmacophore features

Affiliations: School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou, 510632, China.

Appeared or available online: July 1, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more